IGM Biosciences Stock (NASDAQ:IGMS)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$14.90

52W Range

$3.81 - $22.50

50D Avg

$11.85

200D Avg

$10.36

Market Cap

$914.10M

Avg Vol (3M)

$353.33K

Beta

0.21

Div Yield

-

IGMS Company Profile


IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

204

IPO Date

Sep 18, 2019

Website

IGMS Performance


IGMS Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.13M$1.07M-
Operating Income$-263.46M$-227.96M$-165.32M
Net Income$-246.42M$-214.25M$-160.68M
EBITDA$-263.46M$-227.96M$-165.32M
Basic EPS-$-5.16$-4.80
Diluted EPS-$-5.16$-4.80

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q4 22Mar 31, 23 | 11:06 PM
Q4 20Mar 30, 21 | 11:07 PM
Q4 19Mar 26, 20 | 9:41 PM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
CGEMCullinan Oncology, Inc.
RVMDRevolution Medicines, Inc. Warrant
IKNAIkena Oncology, Inc.
MLYSMineralys Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
ERASErasca, Inc.
CERECerevel Therapeutics Holdings, Inc.
RNAAvidity Biosciences, Inc.
BDTXBlack Diamond Therapeutics, Inc.
BCELAtreca, Inc.
PASGPassage Bio, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.